CROCODILE(00122) announced its financial performance in 2025, with a net loss of 108 million Hong Kong dollars, a year-on-year increase of 116.45%.
Crocodile Apparel Group (00122) announced its performance in 2025, with revenue of HKD 92.285 million, a decrease of 32.95% year-on-year; a net loss of HKD 108 million, an increase of 116.45% year-on-year; and a loss per share of 147.18 HK cents.
CROCODILE (00122) announced its performance for 2025, with revenue of HK$92.285 million, a decrease of 32.95% year-on-year; a net loss of HK$108 million, an increase of 116.45% year-on-year; and a loss per share of 147.18 HK cents.
The announcement stated that the main reasons for the loss were: (i) a revaluation loss of HK$73 million on the group's investment properties (2024: a loss of HK$23 million), which is of a non-cash nature; (ii) a fair value loss of HK$10 million on interest rate swap arrangements (2024: income of HK$5 million); and (iii) financing costs of HK$29 million (2024: HK$63 million).
Related Articles

AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.

CHINA ECOTOUR (01371) is seeking for a restructuring and formulating proposed restructuring terms.

SIMCERE PHARMA (02096): Ma Bao Wen appointed as Co-Secretary of the Company
AK MEDICAL (01789) released its annual performance with a net profit attributable to shareholders of 339 million yuan, a year-on-year increase of 23.8%.

CHINA ECOTOUR (01371) is seeking for a restructuring and formulating proposed restructuring terms.

SIMCERE PHARMA (02096): Ma Bao Wen appointed as Co-Secretary of the Company






